Edwards Lifesciences Corporation (EW)

Market Cap	49.41B +14.1%
Revenue (ttm)	6.51B +14.6%
Net Income	1.00B -75.8%
EPS	1.72 -75.5%
Shares Out	576.40M
PE Ratio	51.15
Forward PE	27.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,083,471
Open	86.54
Previous Close	86.82
Day's Range	85.63 - 87.12
52-Week Range	72.30 - 96.29
Beta	0.85
Analysts	Buy
Price Target	100.96 (+17.77%)
Est. Earnings	Oct 29, 2026

About EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 16,000
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Analyst Summary

According to 29 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $100.96, which is an increase of 17.77% from the latest price.

Price Target

$100.96

(17.77% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 24, 2026

Data Sources Report a data error